Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 2/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31268755 | 1.00 | FABP3 (0.34) | FABP3PDCD1CD274KDM4EALDH1A1 | |
| SCHEMBL31269132 | 0.95 | PDCD1 (0.34) | FABP3PDCD1CD274PIK3CD | |
| SCHEMBL31268870 | 0.95 | PDCD1 (0.34) | FABP3PDCD1CD274PIK3CD | |
| SCHEMBL31269154 | 0.95 | FABP3 (0.34) | FABP3PDCD1CD274PIK3CDHCRTR1 | |
| SCHEMBL31269461 | 0.95 | FABP3 (0.34) | FABP3PDCD1CD274PIK3CDHCRTR1 | |
| SCHEMBL31269079 | 0.90 | PDCD1 (0.34) | PDCD1CD274KDM4EALDH1A1PIK3CD | |
| SCHEMBL31268782 | 0.88 | CTSA (0.34) | PDCD1CD274PIK3CDLMNATSHR | |
| SCHEMBL31268835 | 0.88 | PIK3CD (0.32) | PIK3CDPPARDHCRTR1HCRTR2 | |
| SCHEMBL31269175 | 0.88 | PIK3CD (0.32) | PIK3CDPPARDHCRTR1HCRTR2 | |
| SCHEMBL31269105 | 0.88 | PIK3CD (0.33) | PDCD1CD274KDM4EALDH1A1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |